Panitumumab - Biologic Drug Details

Summary for panitumumab

Tradenames:	1
Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for panitumumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for panitumumab

Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Andrei Iagaru	Phase 2
University of Alabama at Birmingham	Early Phase 1
Anup Kasi	Phase 1/Phase 2

See all panitumumab clinical trials

Recent Litigation for panitumumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
AbbVie Inc. v. Alvotech hf.	2021-05-28
Alvotech USA Inc. v. Abbvie Inc	2021-05-11
AbbVie Inc. v. Alvotech hf.	2021-04-27

See all panitumumab litigation

PTAB Litigation

Petitioner	Date
GEMoaB Monoclonals GmbH	2019-12-20
	2018-03-20
Forty Seven, Inc.	2018-01-08

See all panitumumab litigation

Pharmacology for panitumumab

Mechanism of Action	HER1 Antagonists
Established Pharmacologic Class	Epidermal Growth Factor Receptor Antagonist
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for panitumumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for panitumumab Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2039-02-26	Company disclosures
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2017-05-05	Company disclosures

3) Low Certainty: US Patents for panitumumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2033-03-11	Patent claims search
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2030-04-21	Patent claims search
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2039-02-26	Patent claims search
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147		2031-01-11	Patent claims search

International Patents for panitumumab

Country	Patent Number	Estimated Expiration
European Patent Office	1878746
Spain	2289779
Austria	366747
Japan	2018076321

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122008000028	Germany		PRODUCT NAME: PANITUMUMAB MIT EINEM ANTINEOPLASTISCHEN WIRKSTOFF, INSBESONDERE PANITUMUMAB MIT EINEM ODER MEHREREN DER FOLGENDEN 1 BIS 22: 1 IRINOTECAN 2 CISPLATIN 3 5-FLUORURACIL 4 FOLINSAEURE 5 CISPNSAEURE, 5-FLUORURACIL UND IRINOTECAN =FOLFIRI 9 FOLINSAEURE, 5-FLUORURACIL UND OXALI; REGISTRATION LATIN UND/ODER DOCETAXEL 6 OXALIPLATIN UND/ODER CAPECITABIN 7 IRINOTECAN UND/ODER CYCLOSPORIN 8 FOLINO/DATE: EU/1/07/423/001-003 20071203
08C0022	France		PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001 20071203
344	Finland
C00979246/01	Switzerland		PRODUCT NAME: PANITUMUMABUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57872 14.10.2008